Randomized comparison of adjuvant aromatase inhibitor exemestane (E) plus ovarian function suppression (OFS) vs tamoxifen (T) plus OFS in premenopausal women with hormone receptor positive (HR+) early breast cancer (BC):
Randomized comparison of adjuvant aromatase inhibitor exemestane (E) plus ovarian function suppression (OFS) vs tamoxifen (T) plus OFS in premenopausal women with hormone receptor positive (HR+) early breast cancer (BC):
Cervical cancer kills 270,000 women each year — mainly women in the developing world and in the prime of their productive lives. But cervical cancer is preventable by screening asymptomatic women for precancerous cervical lesions and treating the lesions before they progress to invasive disease. In other words, those deaths are largely preventable. Studies suggest that even if a woman were screened for cervical cancer only once in her lifetime between the ages of 30 and 40, her risk of cancer would be reduced by 25-36%.
Dr. Paul Sabbatini: Recurrent Ovarian Cancer: Now What? (SHARE Program)bkling
On May 22, 2013, SHARE presented "Recurrent Ovarian Cancer: Now What?" The program featured Dr. Ginger Gardner and Dr. Paul Sabbatini of Memorial Sloan-Kettering Cancer Center discussing treatment strategies, as well as new approaches and agents, for managing an ovarian cancer recurrence. Listen to the audio here http://www.sharecancersupport.org/sabbatini.
The information in this presentation is not intended to be a substitute for professional medical advice, diagnosis or treatment.
Don't miss our upcoming webinars: Subscribe today!
In this webinar:
Dr. Paula Gordon will share information on when individuals should start screening for breast cancer, and how often to screen - in order for cancer to be found as early as possible, and to allow the least aggressive options for treatment. Dr. Gordon will also discuss how to screen for recurrence in women who’ve had cancer, explain why these methods are not always offered, and suggest what you can do to improve access to optimal screening.
View the video: https://youtu.be/7uFksz6_4Zk
Follow CCSN on social media:
Twitter - https://twitter.com/survivornetca
Facebook - https://www.facebook.com/CanadianSurvivorNet
Instagram: https://www.instagram.com/survivornet_ca/
Pinterest - https://www.pinterest.com/survivornetwork
Cervical cancer kills 270,000 women each year — mainly women in the developing world and in the prime of their productive lives. But cervical cancer is preventable by screening asymptomatic women for precancerous cervical lesions and treating the lesions before they progress to invasive disease. In other words, those deaths are largely preventable. Studies suggest that even if a woman were screened for cervical cancer only once in her lifetime between the ages of 30 and 40, her risk of cancer would be reduced by 25-36%.
Dr. Paul Sabbatini: Recurrent Ovarian Cancer: Now What? (SHARE Program)bkling
On May 22, 2013, SHARE presented "Recurrent Ovarian Cancer: Now What?" The program featured Dr. Ginger Gardner and Dr. Paul Sabbatini of Memorial Sloan-Kettering Cancer Center discussing treatment strategies, as well as new approaches and agents, for managing an ovarian cancer recurrence. Listen to the audio here http://www.sharecancersupport.org/sabbatini.
The information in this presentation is not intended to be a substitute for professional medical advice, diagnosis or treatment.
Don't miss our upcoming webinars: Subscribe today!
In this webinar:
Dr. Paula Gordon will share information on when individuals should start screening for breast cancer, and how often to screen - in order for cancer to be found as early as possible, and to allow the least aggressive options for treatment. Dr. Gordon will also discuss how to screen for recurrence in women who’ve had cancer, explain why these methods are not always offered, and suggest what you can do to improve access to optimal screening.
View the video: https://youtu.be/7uFksz6_4Zk
Follow CCSN on social media:
Twitter - https://twitter.com/survivornetca
Facebook - https://www.facebook.com/CanadianSurvivorNet
Instagram: https://www.instagram.com/survivornet_ca/
Pinterest - https://www.pinterest.com/survivornetwork
A public webinar to increase awareness on breast cancer. This presentation covers simple facts on occurrence of breast cancer, its risk factors and various symptoms besides briefly highlighting the multitude of treatment options available. Presented in simple layman terms for broad understanding.
About this Webinar: This talk will explore breast screening for women 40-49. The benefits and harms for screening will be discussed, as well as what is unique about breast cancer in women in their 40s. In order to understand the controversy around current guidelines recommending against screening women 40-49, we will review the evidence upon which these guidelines are based, and their impact on breast cancer outcomes for these women.
Report Back from SGO 2023: What’s New in Cervical Cancer?bkling
Curious about what’s new in cervical cancer research? Join Dr. Evelyn Cantillo, gynecologic oncologist at Weill Cornell Medicine, as she shares the latest updates from the Society of Gynecologic Oncology (SGO) 2023 Annual Meeting on Women’s Cancer. Dr. Cantillo will also highlight what the research presented at the conference means for you and answer your questions about the new developments.
Public webinar presentation on breast cancer. This presentation gives an overview of breast cancer in Malaysia, the risk factors and ways to reduce risk of breast cancer, early detection and its importance on survivorship besides exploring treatment options.
Triple Negative Breast Cancer and Women of Color (Slide 1)bkling
In this webinar, Dr. Onyinye D. Balogun and Dr. Lisa Newman of Weill Cornell Medicine-New York Presbyterian Hospital Network discuss all aspects of triple negative breast cancer and its impact on women of color in recognition of Black History Month.
What’s the Latest in Clear Cell Ovarian Cancer?bkling
The understanding of clear cell ovarian cancer is evolving. If you’re diagnosed with clear cell ovarian cancer and eager for information specific to your subtype, we’ve got you covered! Join Dr. Jubilee Brown, Professor and Director of Gynecologic Oncology at Levine Cancer Institute, as she discusses current treatment options and any promising advances. Come with your questions and leave more informed about your subtype.
Similar to Research in the Program for Young Women with Breast Cancer: Past, Present and Future (20)
Commonly thought of as a childhood cancer, leukemia is actually much more common in adults. While symptoms of the disease are consistent among each, researchers are beginning to understand more about underlying biological factors that influence the different ways leukemia develops in children and adults. What are other differences and similarities?
An overview of Clinical Trials for Metastatic HER2-positive Breast Cancer by Dr. Ian Krop, MD, PhD, Chief and Clinical Research Director, Breast Oncology Center at Susan F. Smith Center for Women's Cancers at Dana-Farber Cancer Institute
Overview of clinical trials for metastatic triple-negative breast cancer by Sara M. Tolaney, MD, MPH, Associate Director and Associate Director of Clinical Research at Susan F. Smith Center for Women's Cancers at Dana-Farber Cancer Institute.
Research increasingly shows that “energy balance” is important in breast cancer. Learn why exercise, weight, and diet are important for breast cancer patients.
Prostate cancer is a disease in which cancer forms in the tissues of the prostate, a male gland just below the bladder and in front of the rectum. Prostate cancer is rare in men younger than 50 years of age, and the chance of developing prostate cancer increases as men get older. In the United States, a man has a one in five chance of being diagnosed with prostate cancer in his lifetime.
There are many different pediatric brain tumor types and classifications based upon the tumor’s cell structure, composition, rate of growth, location, and other characteristics. A child’s tumor may have the same microscopic appearance to an adult tumor, but the mutations that cause its growth are completely different.
Soft tissue sarcoma refers to cancer that begins in the muscle, fat, fibrous tissue, blood vessels, or other supporting tissue of the body. View the slideshow to learn more about signs and symptoms of this cancer, as well as risk factors.
Cancer-related fatigue is one of the most common problems patients face. Patients often report feeling wiped out during cancer treatments like chemotherapy and radiation, and for many, feeling tired or worn out continues into life after cancer treatment.
Here are 10 tips for alleviating treatment-related fatigue, through methods such as energy preservation and exercise – the latter of which is now known to be an effective strategy for combating this prevalent side effect.
There are more than 120 different types of brain tumors that may occur in adults. Learn about the five most common types.
For more on brain tumors, visit www.dana-farber.org/braintumor
Multiple myeloma is a type of cancer that begins in plasma cells, white blood cells that produce antibodies. It is also called Kahler's disease, myelomatosis or plasma cell myeloma.
Integrative therapies range from individual treatments, such as acupuncture, massage, and Reiki, to group programs for movement, meditation, and creative arts, as well as exercise and nutritional consultations.
Research conducted by Dana-Farber investigators and others has shown that, when used in conjunction with traditional cancer care, integrative therapies can help ease cancer-related symptoms and improve your quality of life.
HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...GL Anaacs
Contact us if you are interested:
Email / Skype : kefaya1771@gmail.com
Threema: PXHY5PDH
New BATCH Ku !!! MUCH IN DEMAND FAST SALE EVERY BATCH HAPPY GOOD EFFECT BIG BATCH !
Contact me on Threema or skype to start big business!!
Hot-sale products:
NEW HOT EUTYLONE WHITE CRYSTAL!!
5cl-adba precursor (semi finished )
5cl-adba raw materials
ADBB precursor (semi finished )
ADBB raw materials
APVP powder
5fadb/4f-adb
Jwh018 / Jwh210
Eutylone crystal
Protonitazene (hydrochloride) CAS: 119276-01-6
Flubrotizolam CAS: 57801-95-3
Metonitazene CAS: 14680-51-4
Payment terms: Western Union,MoneyGram,Bitcoin or USDT.
Deliver Time: Usually 7-15days
Shipping method: FedEx, TNT, DHL,UPS etc.Our deliveries are 100% safe, fast, reliable and discreet.
Samples will be sent for your evaluation!If you are interested in, please contact me, let's talk details.
We specializes in exporting high quality Research chemical, medical intermediate, Pharmaceutical chemicals and so on. Products are exported to USA, Canada, France, Korea, Japan,Russia, Southeast Asia and other countries.
These lecture slides, by Dr Sidra Arshad, offer a quick overview of physiological basis of a normal electrocardiogram.
Learning objectives:
1. Define an electrocardiogram (ECG) and electrocardiography
2. Describe how dipoles generated by the heart produce the waveforms of the ECG
3. Describe the components of a normal electrocardiogram of a typical bipolar leads (limb II)
4. Differentiate between intervals and segments
5. Enlist some common indications for obtaining an ECG
Study Resources:
1. Chapter 11, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 9, Human Physiology - From Cells to Systems, Lauralee Sherwood, 9th edition
3. Chapter 29, Ganong’s Review of Medical Physiology, 26th edition
4. Electrocardiogram, StatPearls - https://www.ncbi.nlm.nih.gov/books/NBK549803/
5. ECG in Medical Practice by ABM Abdullah, 4th edition
6. ECG Basics, http://www.nataliescasebook.com/tag/e-c-g-basics
Recomendações da OMS sobre cuidados maternos e neonatais para uma experiência pós-natal positiva.
Em consonância com os ODS – Objetivos do Desenvolvimento Sustentável e a Estratégia Global para a Saúde das Mulheres, Crianças e Adolescentes, e aplicando uma abordagem baseada nos direitos humanos, os esforços de cuidados pós-natais devem expandir-se para além da cobertura e da simples sobrevivência, de modo a incluir cuidados de qualidade.
Estas diretrizes visam melhorar a qualidade dos cuidados pós-natais essenciais e de rotina prestados às mulheres e aos recém-nascidos, com o objetivo final de melhorar a saúde e o bem-estar materno e neonatal.
Uma “experiência pós-natal positiva” é um resultado importante para todas as mulheres que dão à luz e para os seus recém-nascidos, estabelecendo as bases para a melhoria da saúde e do bem-estar a curto e longo prazo. Uma experiência pós-natal positiva é definida como aquela em que as mulheres, pessoas que gestam, os recém-nascidos, os casais, os pais, os cuidadores e as famílias recebem informação consistente, garantia e apoio de profissionais de saúde motivados; e onde um sistema de saúde flexível e com recursos reconheça as necessidades das mulheres e dos bebês e respeite o seu contexto cultural.
Estas diretrizes consolidadas apresentam algumas recomendações novas e já bem fundamentadas sobre cuidados pós-natais de rotina para mulheres e neonatos que recebem cuidados no pós-parto em unidades de saúde ou na comunidade, independentemente dos recursos disponíveis.
É fornecido um conjunto abrangente de recomendações para cuidados durante o período puerperal, com ênfase nos cuidados essenciais que todas as mulheres e recém-nascidos devem receber, e com a devida atenção à qualidade dos cuidados; isto é, a entrega e a experiência do cuidado recebido. Estas diretrizes atualizam e ampliam as recomendações da OMS de 2014 sobre cuidados pós-natais da mãe e do recém-nascido e complementam as atuais diretrizes da OMS sobre a gestão de complicações pós-natais.
O estabelecimento da amamentação e o manejo das principais intercorrências é contemplada.
Recomendamos muito.
Vamos discutir essas recomendações no nosso curso de pós-graduação em Aleitamento no Instituto Ciclos.
Esta publicação só está disponível em inglês até o momento.
Prof. Marcus Renato de Carvalho
www.agostodourado.com
NVBDCP.pptx Nation vector borne disease control programSapna Thakur
NVBDCP was launched in 2003-2004 . Vector-Borne Disease: Disease that results from an infection transmitted to humans and other animals by blood-feeding arthropods, such as mosquitoes, ticks, and fleas. Examples of vector-borne diseases include Dengue fever, West Nile Virus, Lyme disease, and malaria.
Title: Sense of Smell
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the primary categories of smells and the concept of odor blindness.
Explain the structure and location of the olfactory membrane and mucosa, including the types and roles of cells involved in olfaction.
Describe the pathway and mechanisms of olfactory signal transmission from the olfactory receptors to the brain.
Illustrate the biochemical cascade triggered by odorant binding to olfactory receptors, including the role of G-proteins and second messengers in generating an action potential.
Identify different types of olfactory disorders such as anosmia, hyposmia, hyperosmia, and dysosmia, including their potential causes.
Key Topics:
Olfactory Genes:
3% of the human genome accounts for olfactory genes.
400 genes for odorant receptors.
Olfactory Membrane:
Located in the superior part of the nasal cavity.
Medially: Folds downward along the superior septum.
Laterally: Folds over the superior turbinate and upper surface of the middle turbinate.
Total surface area: 5-10 square centimeters.
Olfactory Mucosa:
Olfactory Cells: Bipolar nerve cells derived from the CNS (100 million), with 4-25 olfactory cilia per cell.
Sustentacular Cells: Produce mucus and maintain ionic and molecular environment.
Basal Cells: Replace worn-out olfactory cells with an average lifespan of 1-2 months.
Bowman’s Gland: Secretes mucus.
Stimulation of Olfactory Cells:
Odorant dissolves in mucus and attaches to receptors on olfactory cilia.
Involves a cascade effect through G-proteins and second messengers, leading to depolarization and action potential generation in the olfactory nerve.
Quality of a Good Odorant:
Small (3-20 Carbon atoms), volatile, water-soluble, and lipid-soluble.
Facilitated by odorant-binding proteins in mucus.
Membrane Potential and Action Potential:
Resting membrane potential: -55mV.
Action potential frequency in the olfactory nerve increases with odorant strength.
Adaptation Towards the Sense of Smell:
Rapid adaptation within the first second, with further slow adaptation.
Psychological adaptation greater than receptor adaptation, involving feedback inhibition from the central nervous system.
Primary Sensations of Smell:
Camphoraceous, Musky, Floral, Pepperminty, Ethereal, Pungent, Putrid.
Odor Detection Threshold:
Examples: Hydrogen sulfide (0.0005 ppm), Methyl-mercaptan (0.002 ppm).
Some toxic substances are odorless at lethal concentrations.
Characteristics of Smell:
Odor blindness for single substances due to lack of appropriate receptor protein.
Behavioral and emotional influences of smell.
Transmission of Olfactory Signals:
From olfactory cells to glomeruli in the olfactory bulb, involving lateral inhibition.
Primitive, less old, and new olfactory systems with different path
- Video recording of this lecture in English language: https://youtu.be/lK81BzxMqdo
- Video recording of this lecture in Arabic language: https://youtu.be/Ve4P0COk9OI
- Link to download the book free: https://nephrotube.blogspot.com/p/nephrotube-nephrology-books.html
- Link to NephroTube website: www.NephroTube.com
- Link to NephroTube social media accounts: https://nephrotube.blogspot.com/p/join-nephrotube-on-social-media.html
The prostate is an exocrine gland of the male mammalian reproductive system
It is a walnut-sized gland that forms part of the male reproductive system and is located in front of the rectum and just below the urinary bladder
Function is to store and secrete a clear, slightly alkaline fluid that constitutes 10-30% of the volume of the seminal fluid that along with the spermatozoa, constitutes semen
A healthy human prostate measures (4cm-vertical, by 3cm-horizontal, 2cm ant-post ).
It surrounds the urethra just below the urinary bladder. It has anterior, median, posterior and two lateral lobes
It’s work is regulated by androgens which are responsible for male sex characteristics
Generalised disease of the prostate due to hormonal derangement which leads to non malignant enlargement of the gland (increase in the number of epithelial cells and stromal tissue)to cause compression of the urethra leading to symptoms (LUTS
Prix Galien International 2024 Forum ProgramLevi Shapiro
June 20, 2024, Prix Galien International and Jerusalem Ethics Forum in ROME. Detailed agenda including panels:
- ADVANCES IN CARDIOLOGY: A NEW PARADIGM IS COMING
- WOMEN’S HEALTH: FERTILITY PRESERVATION
- WHAT’S NEW IN THE TREATMENT OF INFECTIOUS,
ONCOLOGICAL AND INFLAMMATORY SKIN DISEASES?
- ARTIFICIAL INTELLIGENCE AND ETHICS
- GENE THERAPY
- BEYOND BORDERS: GLOBAL INITIATIVES FOR DEMOCRATIZING LIFE SCIENCE TECHNOLOGIES AND PROMOTING ACCESS TO HEALTHCARE
- ETHICAL CHALLENGES IN LIFE SCIENCES
- Prix Galien International Awards Ceremony
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...kevinkariuki227
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Verified Chapters 1 - 19, Complete Newest Version.pdf
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Verified Chapters 1 - 19, Complete Newest Version.pdf
Tom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness Journeygreendigital
Tom Selleck, an enduring figure in Hollywood. has captivated audiences for decades with his rugged charm, iconic moustache. and memorable roles in television and film. From his breakout role as Thomas Magnum in Magnum P.I. to his current portrayal of Frank Reagan in Blue Bloods. Selleck's career has spanned over 50 years. But beyond his professional achievements. fans have often been curious about Tom Selleck Health. especially as he has aged in the public eye.
Follow us on: Pinterest
Introduction
Many have been interested in Tom Selleck health. not only because of his enduring presence on screen but also because of the challenges. and lifestyle choices he has faced and made over the years. This article delves into the various aspects of Tom Selleck health. exploring his fitness regimen, diet, mental health. and the challenges he has encountered as he ages. We'll look at how he maintains his well-being. the health issues he has faced, and his approach to ageing .
Early Life and Career
Childhood and Athletic Beginnings
Tom Selleck was born on January 29, 1945, in Detroit, Michigan, and grew up in Sherman Oaks, California. From an early age, he was involved in sports, particularly basketball. which played a significant role in his physical development. His athletic pursuits continued into college. where he attended the University of Southern California (USC) on a basketball scholarship. This early involvement in sports laid a strong foundation for his physical health and disciplined lifestyle.
Transition to Acting
Selleck's transition from an athlete to an actor came with its physical demands. His first significant role in "Magnum P.I." required him to perform various stunts and maintain a fit appearance. This role, which he played from 1980 to 1988. necessitated a rigorous fitness routine to meet the show's demands. setting the stage for his long-term commitment to health and wellness.
Fitness Regimen
Workout Routine
Tom Selleck health and fitness regimen has evolved. adapting to his changing roles and age. During his "Magnum, P.I." days. Selleck's workouts were intense and focused on building and maintaining muscle mass. His routine included weightlifting, cardiovascular exercises. and specific training for the stunts he performed on the show.
Selleck adjusted his fitness routine as he aged to suit his body's needs. Today, his workouts focus on maintaining flexibility, strength, and cardiovascular health. He incorporates low-impact exercises such as swimming, walking, and light weightlifting. This balanced approach helps him stay fit without putting undue strain on his joints and muscles.
Importance of Flexibility and Mobility
In recent years, Selleck has emphasized the importance of flexibility and mobility in his fitness regimen. Understanding the natural decline in muscle mass and joint flexibility with age. he includes stretching and yoga in his routine. These practices help prevent injuries, improve posture, and maintain mobilit
New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...i3 Health
i3 Health is pleased to make the speaker slides from this activity available for use as a non-accredited self-study or teaching resource.
This slide deck presented by Dr. Kami Maddocks, Professor-Clinical in the Division of Hematology and
Associate Division Director for Ambulatory Operations
The Ohio State University Comprehensive Cancer Center, will provide insight into new directions in targeted therapeutic approaches for older adults with mantle cell lymphoma.
STATEMENT OF NEED
Mantle cell lymphoma (MCL) is a rare, aggressive B-cell non-Hodgkin lymphoma (NHL) accounting for 5% to 7% of all lymphomas. Its prognosis ranges from indolent disease that does not require treatment for years to very aggressive disease, which is associated with poor survival (Silkenstedt et al, 2021). Typically, MCL is diagnosed at advanced stage and in older patients who cannot tolerate intensive therapy (NCCN, 2022). Although recent advances have slightly increased remission rates, recurrence and relapse remain very common, leading to a median overall survival between 3 and 6 years (LLS, 2021). Though there are several effective options, progress is still needed towards establishing an accepted frontline approach for MCL (Castellino et al, 2022). Treatment selection and management of MCL are complicated by the heterogeneity of prognosis, advanced age and comorbidities of patients, and lack of an established standard approach for treatment, making it vital that clinicians be familiar with the latest research and advances in this area. In this activity chaired by Michael Wang, MD, Professor in the Department of Lymphoma & Myeloma at MD Anderson Cancer Center, expert faculty will discuss prognostic factors informing treatment, the promising results of recent trials in new therapeutic approaches, and the implications of treatment resistance in therapeutic selection for MCL.
Target Audience
Hematology/oncology fellows, attending faculty, and other health care professionals involved in the treatment of patients with mantle cell lymphoma (MCL).
Learning Objectives
1.) Identify clinical and biological prognostic factors that can guide treatment decision making for older adults with MCL
2.) Evaluate emerging data on targeted therapeutic approaches for treatment-naive and relapsed/refractory MCL and their applicability to older adults
3.) Assess mechanisms of resistance to targeted therapies for MCL and their implications for treatment selection
Flu Vaccine Alert in Bangalore Karnatakaaddon Scans
As flu season approaches, health officials in Bangalore, Karnataka, are urging residents to get their flu vaccinations. The seasonal flu, while common, can lead to severe health complications, particularly for vulnerable populations such as young children, the elderly, and those with underlying health conditions.
Dr. Vidisha Kumari, a leading epidemiologist in Bangalore, emphasizes the importance of getting vaccinated. "The flu vaccine is our best defense against the influenza virus. It not only protects individuals but also helps prevent the spread of the virus in our communities," he says.
This year, the flu season is expected to coincide with a potential increase in other respiratory illnesses. The Karnataka Health Department has launched an awareness campaign highlighting the significance of flu vaccinations. They have set up multiple vaccination centers across Bangalore, making it convenient for residents to receive their shots.
To encourage widespread vaccination, the government is also collaborating with local schools, workplaces, and community centers to facilitate vaccination drives. Special attention is being given to ensuring that the vaccine is accessible to all, including marginalized communities who may have limited access to healthcare.
Residents are reminded that the flu vaccine is safe and effective. Common side effects are mild and may include soreness at the injection site, mild fever, or muscle aches. These side effects are generally short-lived and far less severe than the flu itself.
Healthcare providers are also stressing the importance of continuing COVID-19 precautions. Wearing masks, practicing good hand hygiene, and maintaining social distancing are still crucial, especially in crowded places.
Protect yourself and your loved ones by getting vaccinated. Together, we can help keep Bangalore healthy and safe this flu season. For more information on vaccination centers and schedules, residents can visit the Karnataka Health Department’s official website or follow their social media pages.
Stay informed, stay safe, and get your flu shot today!
Research in the Program for Young Women with Breast Cancer: Past, Present and Future
1. Research in the Program for Young
Women with Breast Cancer:
Past, Present and Future
Shoshana Rosenberg, ScD and
Ann H. Partridge, MD MPH
Dana-Farber Cancer Institute
January 24, 2018
2. • In 2005, we established The Program for Young Women
with Breast Cancer (“Young and Strong”) to address the
unique issues facing the young patients at DFCI
• The program addresses critical issues including:
Fertility
Genetics
Parenting
Sexual functioning
Psychosocial and Emotional Health
Exercise and Nutrition
Balancing School and/or a Career
Building Relationships
• Initially, the program served women diagnosed at age
42 and younger but include women up to 45 now
• To date: directly served over 4,000 new young patients
visiting our breast oncology clinics
3. A Comprehensive and Integrated Program
Focused on Young Women
Clinical Care
Research
Education
(both patient and provider)
5. Helping Ourselves, Helping Others:
The Young Women’s Breast Cancer Study (YWS)
Prospective cohort established in 2006
• Women age ≤40 at diagnosis of breast cancer
• Eastern Massachusetts, Colorado, MN, Canada
Outcomes
• Disease, tumor biology/molecular characteristics
• Treatment issues (surgical decisions, adherence)
• Psycho-social (fertility, sexuality, workplace issues)
• Lifestyle factors (alcohol, exercise, weight gain)
• Health services (delay in diagnosis, survivorship care)
Accrual
• 1302 participants enrolled
• Surveys: every 6 months x 3 years, annually thereafter
• Blood: 91% of patients with at least one sample
• Tumor: 98% consented, centrally reviewed by study pathologists,
block banked for future research
PI: Partridge
Co-PI: Rosenberg
6. Participating Sites
o Brigham and Women’s Hospital/DFCI
o Faulkner Hospital
o Massachusetts General Hospital
o Beth Israel Deaconess Medical Center
o South Shore Hospital
o Mass General/North Shore Cancer Center
o Cape Cod Healthcare
o Lowell General Hospital
o Newton Wellesley Hospital
o Sunnybrook Health Sciences Center
o University of Colorado – Denver
o Mayo Clinic
o Also, related studies on-going in Europe, Saudi Arabia, Israel
7. Recruitment
• Inclusion Criteria
• Female
• New diagnosis of breast cancer (no history of breast cancer)
• Stage 0-4 included but exclude pure LCIS
• Age 40 or younger at diagnosis
• Informed consent obtained from patient
• Ability to understand written and spoken English to the extent necessary to complete
the questionnaires
• At Partners institutions, potentially eligible cases were identified from review of tumor
registry lists
• At some sites, research nurses and/or research coordinators assisted with recruitment
via review of patient lists
8. Study/Survey timeline
All surveys are sent based on patients’date of
diagnosis, except the baseline and 6 month surveys
Consent
Survey 1
Blood
sample
Survey 2 Survey 3
Blood
sample
Survey 4
Med Rec
Request
Tissue
Request
Survey 5 Survey 6
3 year 20 year =
annual surveys
4 year = final blood
sample
7, 10 year = LTF Re-
engagement
Baseline 6 mos 1 yr 18 mos 2 yrs 30 mos 3 20 yrs
9. Some examples of survey measures
• Socio-demographics
• Medical and family history
• Genetics
• Fertility issues and outcomes
• General quality of life
• Anxiety and depression
• Menopausal symptoms
• Physical activity
10. Timepoint Range
Baseline Enrollment – 9 months post diagnosis
1 Year 9 months – 2 years post diagnosis
4 year 3.5 years – 5 years post diagnosis
Blood Specimen Collection
• We work with coordinators at participating sites to arrange these draws or we
send blood kits directly to the patients with appointments offsite
• We process these specimens and isolate whole blood + plasma before freezing
them for future studies
• 1224/1302 =94% women have consented to blood
• Of these, >90% have contributed at least one sample
11. Tissue Specimen Collection
• We collect specimens to characterize the
tumors and bank for future studies
utilizing:
• molecular evaluations of disease
characteristics (via TMA)
• genetic variability (via whole exome
sequencing)
• 1278/1302=98% have consented to
pathology specimen collection
• Of these, >80% have undergone
pathology review
12. Overview of selected completed/
Ongoing studies
• Pathologic features and biology of breast cancer in
young women
• Health care delivery
• Local therapy and patient decision making
• Fertility and pregnancy issues
• Psycho-social and quality of life issues
13. Pathologic features/molecular phenotype
• Pathologic features and molecular phenotype by
patient age in a large cohort of young women with
breast cancer
• Molecular Phenotype of Breast Cancer According to
Time Since Last Pregnancy in a Large Cohort of
Young Women
14. Collins et al. BCRT 2012
• N=399 women
• No differences in clinico-pathologic phenotype by age
• 35% were luminal B
15. Collins et al. The Oncologist 2015
• N=707 women
• No association with parity or recency of pregnancy and
molecular phenotype, adjusting for age at diagnosis and family
history
16. Health care delivery
• Breast cancer presentation and diagnostic delays in
young women
• BRCA1 and BRCA2 mutation testing in young
women with breast cancer
19. • Perceptions, knowledge, and satisfaction with
contralateral prophylactic mastectomy among
young women with breast cancer: a cross-sectional
survey
• Local therapy decision-making and contralateral
prophylactic mastectomy in young women with
early-stage breast cancer
Local therapy
20. • 123 women with unilateral breast cancer, age 40 or
younger at diagnosis who had undergone bilateral
mastectomy
• ~25% BRCA 1 or BRCA 2 mutation carriers
• Median time since surgery: 2.1 (range: 0.1-4.3)
years
• Median age at diagnosis: 37 (26-40) years
• 79% Stage I/II at diagnosis
22. • 560 women with Stage I-III unilateral breast cancer
enrolled in YWS
• Characterization of decision-making process,
including involvement and confidence with the
decision
• Assessment of socio-demographic, clinical and
decisional factors associated with CPM vs. breast
conserving surgery and unilateral mastectomy
24. Local therapy decision-making and CPM in
young women with early-stage breast cancer
Rosenberg et al. Ann Surg Onc 2015
• Among women where BCS was an option or was
recommended, choosing CPM (vs. other types of
surgery) was associated with:
• Testing positive for a BRCA mutation
• Higher levels of generalized anxiety
• Lower BMI
• Lower levels of fear of recurrence
25. Fertility is a primary issue
Ruddy et al, J Clin Oncol, 2014
26. Enrolled in YWS, n=1302
Completed abbreviated
surveys, n=137
No baseline survey,
n=89
YWS: fertility outcomes
Analytic cohort, n=1076
27. Patient, disease, treatment characteristics
Characteristic Patients (n=1076)
Age at diagnosis n (%)
≤30 years (yr) 140 (13)
31-35 years 293 (27)
36 – 40 years 643 (60)
Stage
0 88 (8)
I 355 (33)
II 422 (40)
III 145 (14)
IV 56 (5)
Partnered at diagnosis
Yes 806 (75)
No 263 (25)
Children prior to diagnosis
Yes 691 (64)
No 385 (36)
Phenotype
ER+ 772 (72)
ER- 293 (28)
Adjuvant endocrine therapy
Yes 704 (65)
No 372 (35)
Chemotherapy
Yes 802 (75)
No 270 (25)
Median follow-up:
5 years
30. 87%
70%
64%
13%
30%
36%
0%
20%
40%
60%
80%
100%
≤30 years 31-35 years 36 – 40 years
No TRA
TRA
No amenorrhea
Amenorrhea
100%
60%
0%
40%
0%
20%
40%
60%
80%
100%
No chemotherapy Chemotherapy
No TRA
TRA
No amenorrhea
Amenorrhea
n=69 n=128 n=310 n=111 n=396
76%
64%
24%
36%
0%
20%
40%
60%
80%
No tamoxifen Tamoxifen
No TRA
TRA
No amenorrhea
Amenorrhea
n=188 n=319
Amenorrhea varies by age and use of
chemotherapy and tamoxifen
Poorvu et al, ASCO, 2015
31. Total cohort,
n=1076
Interested,
n= 387 (36%)
Not interested,
n= 689 (64%)
Cumulative pregnancy interest, attempts,
and outcomes
Excluded pregnancies occurring
at time of diagnosis
32. Total cohort,
n=1076
Attempted,
n= 138 (36%)
Interested,
n= 387 (36%)
No attempt,
n= 249 (64%)
Not interested,
n= 689 (64%)
Attempted,
n= 8 (1%)
No attempt,
n= 681 (99%)
Cumulative pregnancy interest, attempts,
and outcomes
Excluded pregnancies occurring
at time of diagnosis
33. Total cohort,
n=1076
Attempted,
n= 138 (36%)
Interested,
n= 387 (36%) Pregnant,
n= 13 (5%)
Not pregnant,
n= 236 (95%)
No attempt,
n= 249 (64%)
Pregnant,
n= 1 (13%)
Not pregnant,
n= 7 (87%)Not interested,
n= 689 (64%)
Pregnant,
n= 9 (1%)
Not pregnant,
n= 672 (99%)
Pregnant,
n= 94 (68%)
Not pregnant,
n= 44 (32%)
Attempted,
n= 8 (1%)
No attempt,
n= 681 (99%)
Cumulative pregnancy interest, attempts,
and outcomes
Excluded pregnancies occurring
at time of diagnosis
34. Total cohort,
n=1076
Attempted,
n= 138 (36%)
Interested,
n= 387 (36%) Pregnant,
n= 13 (5%)
Not pregnant,
n= 236 (95%)
No attempt,
n= 249 (64%)
Pregnant,
n= 1 (13%)
Not pregnant,
n= 7 (87%)Not interested,
n= 689 (64%)
Pregnant,
n= 9 (1%)
Not pregnant,
n= 672 (99%)
Pregnant,
n= 94 (68%)
Not pregnant,
n= 44 (32%)
Attempted,
n= 8 (1%)
No attempt,
n= 681 (99%)
Cumulative pregnancy interest, attempts,
and outcomes
Excluded pregnancies occurring
at time of diagnosis
35. Live births, 108,
61%
Micarriages, 44,
25%
Abortions, 7, 4%
Stillbirths, 2, 1%
TBD, 15,
9% 173 pregnancies
among 117 women
(including 3 sets of
twins)
Median f/u: 5 years
Pregnancy outcomes
36. Psycho-social and Quality of Life
• Body image
• Body image in recently diagnosed young women with early
breast cancer
• Sexual functioning
• Treatment-related amenorrhea and sexual functioning in
young breast cancer survivors
• Anxiety/Depression
• Partner support and anxiety in young women with breast
cancer
• Depression and anxiety symptoms in young women with
metastatic disease
37. • Local therapy and QOL
• Breast-Q (Dominici/Rosenberg)
• Longitudinal analysis of QOL outcomes by surgery type
(Rosenberg)
• Adjuvant systemic therapy
• Endocrine therapy adherence (Wassermann)
• Endocrine therapy initiation and persistence (Rosenberg)
• Psychosocial
• Post-traumatic stress disorder (Vazquez, HMS)
• Trajectories in sexual function (von Hippel, HSPH)
• Experience of partners of young women with breast cancer
(Borstelmann)
Ongoing projects
38. Partner sub-study
• One-time cross-sectional survey of partners of cohort
participants
• Outcomes included social support, quality of life,
coping, parenting concerns, anxiety, depression, post-
traumatic growth, sexual satisfaction
• N=332 respondents
• Almost all respondents were male
• In women not in “active treatment,” median follow-up from
(patient) diagnosis to survey of partner was 58 months
39. Concern N (%) Missing N
Anxiety (HADS subscore ≥8) 106 (42) 39
Depression (HADS subscore ≥8) 47 (21) 60
Parenting concerns (N=208 with children) 74 (36) 4
Relationship strain 89 (32) 12
Financial insecurity 79 (29) 17
Not sexually active 55 (20) 12
Maladaptive coping style 120 (44) 19
Social support (MOS-SS summary score) Median
(range)
67 (19-95)
15
Table 2. Prevalence of psychosocial concerns in partners (N=289)
Abbreviations: HADS, Hospital Anxiety and Depression Scale; MOS-SS, Medical Outcomes
Survey-Social Support Survey
• Many partners of breast cancer survivors experience substantial psychosocial
distress
• In an analysis of factors associated with anxiety, maladaptive coping during
treatment was associated with higher levels of anxiety
• Attention to the psycho-social health of caregivers is critical during both the
treatment and survivorship phases of care
40. • Biology
• Understanding the genomic underpinnings of breast
cancer in young women (Wagle)
• ctDNA to identify MRD and risk of recurrence in young
women (Parsons)
• Whole Exome Sequencing of Treatment Resistant HER2+
Breast Cancer (Wagle/Waks)
• Whole Exome Sequencing of Triple Negative Breast
Cancer (Stover)
Ongoing projects
41.
42. PATHWAYS TO WELLNESS STUDY
Improving Outcomes for Younger Breast Cancer Survivors: A randomized trial comparing
outcomes for women receiving a mindfulness awareness practice group intervention, a
health education curriculum tailored to younger women, or a delayed intervention control
condition PIs: Ganz
and Bower
• Based on successful randomized pilot data from a single
site pilot randomized trial at UCLA
• 3 arm, multi-center RCT evaluating mindfulness vs. ed. vs.
control
• 6 week intervention teaching mindfulness awareness
practices (MAPs)
• Sitting and walking meditations
• Application to physical symptoms, emotions, and
thoughts
• Focus on relevance for cancer survivorship
44. Pregnancy Outcome and Safety of Interrupting Therapy
for women with endocrine responsIVE Breast Cancer
IBCSG 48-14 / BIG 8-13
ALLIANCE # A221405
POSITIVE TRIAL
INTERNATIONAL PI: OLIVIA PAGANI
NORTH AMERICAN PI: ANN PARTRIDGE
45. The POSITIVE Trial: Endocrine therapy interruption for
pregnancy in breast cancer patients
• Phase II trial designed to evaluate safety and
pregnancy outcomes of interrupting ET for young
women with ER+ disease who desire pregnancy
• Enroll 512 women, <42, premenopausal, have
completed between 18-30 months of ET
• Study participants come off endocrine therapy for
up to 2 years for a pregnancy attempt, restart
hormonal therapy
• Outcomes: disease, reproductive, psychosocial
46. YWS2: from observation to intervention
Diagnosis Treatment Long-term
Survivorship
Enrollment
Surgical DA
Mindfulness
intervention
Symptom management to
improve ET adherence
6 mo 12 mo
Addressing menopausal
sx, sexual dysfunction
Expanding TS/SCP+
research pilot
47. Thank you!
DFCI/YWS Team
Ann Partridge, PI
Shoshana Rosenberg, co-PI
Eric Winer
Rulla Tamimi
Laura Collins
Katie Ruddy
Judy Garber
Nick Wagle
Lidia Schapira
Jeff Peppercorn
Elana Brachtel
Steve Come
Ginger Borges
Ellen Warner
Shari Gelber
Phil Poorvu
The Program for Young Women Team
Kim Sprunck-Harrild
Craig Snow
Allison Higgins
Rachel Gaither
Sarah Walsh
Eric Brosnan
Megan Meyer
Sonja Darai
Stephanie Cram
Sylvia Ilahuka